Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non-alcoholic fatty liver disease


  • Elnaz Jafarvand Department of Nutrition in Community, School of Nutrition, Tabriz University of Medical Sciences, Tabriz
  • Mahdieh Abbasalizad Farhangi Department of Nutrition in Community, School of Nutrition, Tabriz University of Medical Sciences, Tabriz
  • Beytollah Alipour Department of Nutrition in Community, School of Nutrition, Tabriz University of Medical Sciences, Tabriz
  • Manouchehr Khoshbaten Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz




Coenzyme Q10, Lipid profile, Liver enzyme, Non-alcoholic fatty liver disease


This randomized double-blind placebo-controlled trial was conducted on 41 patients with non-alcoholic fatty liver disease. Patients in intervention group received 100 mg/day coenzyme Q10 (CoQ10) for four weeks. There was a significant reduction in waist circumference and aspartate aminotransferase concentrations after CoQ10 supplementation (p<0.05). Dietary fiber was in negative correlation with change in serum alanine aminotransferase (ALT) concentrations (r = -410, p = 0.04), and dietary fat intake was in positive relation with serum triglyceride (r = 463, p = 0.04) and in negative relation with serum high-density lipoprotein cholesterol (HDL-C) (r = -533, p = 0.02) in CoQ10-treated group. CoQ10 supplement is able to reduce central obesity and improve liver function in non-alcoholic fatty liver disease. Dietary factors were also significant determinants of change in liver-specific enzyme ALT and lipid profile in these patients. Further trials with higher dose of CoQ10 and longer treatment periods are warranted to better clarify these findings.



Download data is not yet available.
1979 Read


Alam MA, Rahman MM. Mitochondrial dysfunction in obesity: Potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord. 2014; 13: 1-13.

Ali SA, Faddah L, Abdel-Baky A , Bayoumi A. Protective effect of l-carnitine and coenzyme Q10 on CCL4-induced liver injury in rats. Sci Pharm. 2010; 78: 881-96.

Amimoto T, Matsura T, Koyama S, Nakanishi T, Yamada K , Kajiyama G. Acetaminophen-induced hepatic injury in mice: The role of lipid peroxidation and effects of pretreatment with coenzyme Q10 and alpha-tocopherol. Free Radic Biol Med. 1995; 19: 169-76.

Bour S, Carmona MC, Galinier A, Caspar-Bauguil S, Van Gaal L, Staels B, Pénicaud L , Casteilla L. Coenzyme Q as an antiadipogenic factor. Antioxid Redox Signal. 2011; 14: 403-13.

Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, Grundy SM , Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-95.

Carmona MC, Lefebvre P, Lefebvre B, Galinier A, Bénani A, Jeanson Y, Louche K, Flajollet S, Ktorza A , Dacquet C. Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice. Int J Obes. 2009; 33: 204-11.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M , AJS. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.

Choo H, Kim J, Kwon O, Lee C, Mun J, Han S, Yoon Y, Yoon G, Choi K, Ko Y. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia 2006; 49: 784-91.

Consultation WE. Waist circumference and waist-hip ratio. 2011.

Esfahani SA, Esmaeilzadeh E, Bagheri F, Emami Y, Farjam M. The effect of co-enzyme Q10 on acute liver damage in rats: A biochemical and pathological study. Hepat Mon. 2013; 13: e13685.

Farhangi MA, Alipour B, Jafarvand E, Khoshbaten M. Oral coenzyme Q10 supplementation in patients with non-alcoholic fatty liver disease: Effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Arch Med Res. 2014; 45: 589-95.

Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002; 22: 1592-99.

Fouad AA, Jresat I. Hepatoprotective effect of coenzyme Q10 in rats with acetaminophen toxicity. Environ Toxicol Pharmacol. 2012; 33: 158-67.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.

Hashemi M, Bahari A, Bahari G, Ghavami S. Coenzyme Q10 may be effective in the treatment of non alcoholic fatty liver disease (NAFLD). Irn J Med Hypotheses Ideas. 2008; 2: 1-4.

Hathcock JN, Shao A. Risk assessment for coenzyme Q10 (Ubiquinone). Regul Toxicol Pharmacol. 2006; 45: 282-88.

Ikematsu H, Nakamura K, Harashima S, Fujii K, Fukutomi N. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol. 2006; 44: 212-18.

International Physical Activity Questionnaire (IPAQ) guidelines for data processing and analysis of the international physical activity questionnaire. November 2005. Available from: http://www.ipaq.ki.se/scoring.pdf.

Jimenez-Santo MA, Juarez-Rojop IE, Tovilla-Zarate CA, Espinosa-Garcia MT, Juarez-Oropeza MA, Ramon-Frias T, Bermudez-Ocana DY, Díaz-Zagoya JC. Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet. Lipids Health Dis. 2014; 13: 1-10.

Kani AH, Alavian SM, Haghighatdoost F, Azadbakht L. Diet macronutrients composition in non-alcoholic fatty liver disease: A review on the related documents. Hepat Mon. 2014; 14: 1-9.

K?dziora-Kornatowska K, Czuczejko J, Motyl J, Szewczyk-Golec K, Kozakiewicz M, Pawluk H, K?dziora J, B?aszczak R, Banach M , Rysz J. Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide: A pilot study. Arch Med Sci. 2010; 6: 513-18.

Lee SK, Lee JO, Kim JH, Kim N, You GY, Moon JW, Sha J, Kim SJ, Lee YW , Kang HJ. Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPAR? induction in 3T3-L1 preadipocytes. Cell Signal. 2012; 24: 2329-36.

Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, Koizumi J. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study. Atherosclerosis 2007; 195: 182-89.

Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with non-alcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006; 40: 930-35.

Madrazo JA, Kelly DP. The PPAR trio: Regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol. 2008; 44: 968-75.

Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: A systematic review. J Am Coll Cardiol. 2007; 49: 2231-37.

Miles MV. The uptake and distribution of coenzyme Q10. Mitochondrion 2007; 7: 72-77.

Mohammadshahi M, Farsi F, Nejad PA, Hajiani E, Zarei M, Engali KA. The coenzyme Q10 supplementation effects on lipid profile, fasting blood sugar, blood pressure and oxidative stress status among non-alcoholic fatty liver disease patients: A randomized, placebo-controlled, pilot study. J Gastroenterol Hepatol Res. 2014; 3: 1108-13.

Mouzaki M, Allard J. Non-alcoholic steatohepatitis: The therapeutic challenge of a global epidemic. Ann Gastroenterol. 2012; 25: 207-17.

Othman AA, Shoheib ZS, Abdel-Aleem GA, Shareef MM. Experimental schistosomal hepatitis: Protective effect of coenzyme-Q10 against the state of oxidative stress. Exp Parasitol. 2008; 120: 147-55.

Papandreou D, Karabouta Z, Pantoleon A, Rousso I. Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease. Appetite 2012; 59: 939-44.

Ross AB, Godin JP, Minehira K, Kirwan JP. Increasing whole grain intake as part of prevention and treatment of non-alcoholic fatty liver disease. Int J Endocrinol. 2013; 2013: 1-13.

Sohet FM, Neyrinck AM, Pachikian BD, de Backer FC, Bindels LB, Niklowitz P, Menke T, Cani PD, Delzenne NM. Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochem Pharmacol. 2009; 78: 1391-400.

Sumimoto K, Inagaki K, Ito H, Marubayashi S, Yamada K, Kawasaki T, Dohi K. Ischemic damage prevention by co-enzyme Q10 treatment of the donor before orthotopic liver transplantation: Biochemical and histologic findings. Surgery 1987; 102: 821-27.

Thomas AP, Dunn TN, Drayton JB, Oort PJ, Adams SH. A dairy-based high calcium diet improves glucose homeostasis and reduces steatosis in the context of preexisting obesity. Obesity 2013; 21: E229-35.

Wei Y, Rector RS, Thyfault JP, Ibdah JA. Non-alcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol. 2008; 14: 193.

Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu SY, Erdil A, Ates Y, Aslan M. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100: 850-55.



How to Cite

Jafarvand, E., M. A. Farhangi, B. Alipour, and M. Khoshbaten. “Effects of Coenzyme Q10 Supplementation on the Anthropometric Variables, Lipid Profiles and Liver Enzymes in Patients With Non-Alcoholic Fatty Liver Disease”. Bangladesh Journal of Pharmacology, vol. 11, no. 1, Dec. 2015, pp. 35-42, doi:10.3329/bjp.v11i1.24513.



Clinical Trial